IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
Open accessThe DOI matches its Crossref record; 40 of the 50 references it cites were found in a registry or an index.
Abstract
The anti-tumor activity of recombinant mAb's directed against tumor cell growth receptors has generally been considered to result from direct antiproliferative effects, the induction of apoptosis, or possibly Ab-dependent cellular cytotoxicity mediated against tumor targets.However, it remains unclear to what degree these mechanisms actually aid in the clearance of Ab-coated tumor cells in vivo.We show here that NK cells secrete a distinct profile of potent immunostimulatory cytokines in response to dual stimulation with Ab-coated tumor cells and IL-12.This response could not be duplicated by costimulation with other ILs and was significantly enhanced in the presence of monocytes.Cytokine production was dependent upon synergistic signals mediated by the activating receptor for the Fc portion of IgG (FcγRIII) and the IL-12 receptor expressed on NK cells.Coadministration of Ab-coated tumor cells and IL-12 to BALB/c mice resulted in enhanced circulating levels of NK cell-derived cytokines with the capacity to augment anti-tumor immunity.These findings suggest that, in addition to mediating cellular cytotoxicity and apoptosis, the anti-tumor activity of mAb's might also result from activation of a potent cytokine secretion program within immune effectors capable of recognizing mAb-coated targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, increase in IL-12 levels might enhance the efficacy of immunotherapy by increasing the production of IFN-ɤ to stimulate the development and enhance the cytotoxicity of activated NK cells (100) and T cells and to accelerate the differentiation of CD4+ Th0 cells toward the Th1 phenotype, thus improving antibody-dependent cellular cytotoxicity (101).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [100]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune Responses
Gately, M. K., Renzetti, L. M., Magram, J., Stern, A. S., Adorini, L., Gubler, U., & Presky, D. H. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.495 · Cited by 1,231
Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells
Thierfelder, W. E., van Deursen, J. M., Yamamoto, K., Tripp, R. A., Sarawar, S. R., Carson, R. T., Sangster, M. Y., Vignali, D. A. A., Doherty, P. C., Grosveld, G. C., et al. (1996) · Nature · doi:10.1038/382171a0 · Cited by 1,180
Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., & Caligiuri, M. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1395 · Cited by 1,092
Self-citationPegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Biology and clinical relevance of human natural killer cells
Robertson, M., & Ritz, J. (1990) · Blood · doi:10.1182/blood.v76.12.2421.2421 · Cited by 931
Research works printed but not linked: 10
- Sarup, J.C., et al. 1991. Characterization of an anti-p185HER2 mono- clonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1:72-82.
- Baselga, J., and Albanell, J. 2001. Mechanisms of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12:S35-S41. · doi:10.1023/a:1011163824080
- Sliwkowski, M.X., et al. 1999. Nonclinical studies addressing the mech- anism of action of trastuzumab (Herceptin). Semin. Oncol. 26:60-70.
- Penichet, M.L., et al. 1999. In vivo properties of three human HER2/neu- expressing murine cell lines in immunocompetent mice. Lab. Anim. Sci. 49:179-188.
- Fleming, G.F., et al. 1999. A phase I CALGB trial of recombinant human anti-HER2 monoclonal antibody plus low-dose interleukin2 in solid tumors. Proc. Am. Soc. Clin. Oncol. 18:184a. (Abstr. 710)
- Weiner, L.M., et al. 1995. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 55:4586-4593.
- Penichet, M.L., Dela Cruz, J.S., Shin, S.U., and Morrison, S.L. 2001. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Hum. Antibodies. 10:43-49. · doi:10.3233/hab-2000-10107
- Peng, L.S., Penichet, M.L., and Morrison, S.L. 1999. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity. J. Immunol. 163:250-258. · doi:10.4049/jimmunol.163.1.250
- Cavallo, F., et al. 1999. Immune events associated with the cure of estab- lished tumors and spontaneous metastases by local and systemic inter- leukin-12. Cancer Res. 59:414-421.
- Parihar, R. et al. 2001. A phase I trial of Herceptin and interleukin-12 in patients with HER2-overexpressing malignancies. Proc. Am. Soc. Clin. Oncol. 20:258a. (Abstr. 1031)
Cited by
Items 101–200 of 212
Turin, I., Delfanti, S., Ferulli, F., Brugnatelli, S., Tanzi, M., Maestri, M., Cobianchi, L., Lisini, D., Luinetti, O., Paulli, M., et al. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000205 · Cited by 29
Altaie, A. M., Venkatachalam, T., Samaranayake, L. P., Soliman, S. S. M., & Hamoudi, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.707267 · Cited by 28
Antitumor Activities of Interleukin-12 in Melanoma
Gao, W., Pan, J., & Pan, J. (2022) · Cancers · doi:10.3390/cancers14225592 · Cited by 27
Sun, L., Wang, R.-C., Zhang, Q., & Guo, L. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153032 · Cited by 27
IL-15 Promotes Polyfunctional NK Cell Responses to Influenza by Boosting IL-12 Production
Wagstaffe, H. R., Nielsen, C. M., Riley, E. M., & Goodier, M. R. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701614 · Cited by 26
Toll-like Receptor 2 Ligands Regulate Monocyte Fcγ Receptor Expression and Function
Shah, P. A., Fatehchand, K., Patel, H. H., Fang, H., Justiniano, S. E., Mo, X. M., Jarjoura, D. G., Tridandapani, S., & Butchar, J. P. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.449983 · Cited by 26
Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy
Denkert, C., Darb‐Esfahani, S., Loibl, S., Anagnostopoulos, I., & Jöhrens, K. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0261-0 · Cited by 26
Li, Z., Chen, G., Cai, Z., Dong, X., Qiu, L., Xu, H., Zeng, Y., Liu, X., & Liu, J. (2018) · OncoImmunology · doi:10.2139/ssrn.3215548 · Cited by 24
Campbell, A. R., Regan, K., Bhave, N. S., Pattanayak, A., Parihar, R., Stiff, A. R., Trikha, P., Scoville, S. D., Liyanarachchi, S., Kondadasula, S. V., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0142-9 · Cited by 23
Self-citationParihar, R., Trotta, R., Roda, J. M., Ferketich, A. K., Tridandapani, S., Caligiuri, M. A., & Carson, W. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4424 · Cited by 23
Self-citationUse of a nanoporous biodegradable miniature device to regulate cytokine release for cancer treatment
He, H., Grignol, V. P., Karpa, V. I., Yen, C., LaPerle, K., Zhang, X., Jones, N., Liang, M. I., Lesinski, G. B., Ho, W. S. W., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.020 · Cited by 22
Self-citationNajmuddin, S. U. F. S., Amin, Z. M., Tan, S. W., Yeap, S. K., Kalyanasundram, J., Veerakumarasivam, A., Chan, S. C., Chia, S. L., Yusoff, K., & Alitheen, N. B. (2020) · PeerJ · doi:10.7717/peerj.9761 · Cited by 22
Kim, S., Park, C. I., Lee, S., Choi, H. R., & Kim, C. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1062365 · Cited by 21
Wang, Y., An, E., Kim, S., You, S., & Jin, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910608 · Cited by 21
Wang, H., Nelson, A. G., Wang, B., Zhao, Z., Lim, X. Y., Shi, M., Meehan, L. J., Jia, X., Kedzierska, K., Meehan, B. S., et al. (2022) · Immunology and Cell Biology · doi:10.1111/imcb.12556 · Cited by 21
Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer
Pan, Q., Tang, Y., Wang, Q. J., Li, Y. Q., Zhang, L., Li, X. D., Zhao, J.-J., Weng, D., Liu, Q., Huang, L., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1038017 · Cited by 20
Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions
Skinner, C. C., McMichael, E. L., Jaime‐Ramirez, A. C., Abrams, Z. B., Lee, R. J., & Carson, W. E. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000258 · Cited by 20
Self-citationWidowati, W., Jasaputra, D. K., Onggowidjaja, P., Sumitro, S. B., Widodo, M. A., Afifah, E., Rihibiha, D. D., Rizal, R., Amalia, A., Kusuma, H. S. W., et al. (2019) · Journal of Mathematical and Fundamental Sciences · doi:10.5614/j.math.fund.sci.2019.51.3.1 · Cited by 20
Cubitt, C. C., McClain, E. D., Becker‐Hapak, M., Foltz, J. A., Wong, P., Wagner, J. A., Neal, C. C., Marín, N. D., Marsala, L. I., Foster, M., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.02.009 · Cited by 20
Implications of a ‘Third Signal’ in NK Cells
Khalil, M., Wang, D., Hashemi, E., Terhune, S. S., & Malarkannan, S. (2021) · Cells · doi:10.3390/cells10081955 · Cited by 19
Dickerson, L. K., Carter, J. A., Kohli, K., & Pillarisetty, V. G. (2023) · Gut · doi:10.1136/gutjnl-2023-329650 · Cited by 19
Rahimi, A., Malakoutikhah, Z., Rahimmanesh, I., Ferns, G. A., Nedaeinia, R., Ishaghi, S. M. M., Dana, N., & Javanmard, S. H. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03134-y · Cited by 19
Bouferraa, Y., Chedid, A., Amhaz, G., Lakkiss, A. E., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158036 · Cited by 18
Genkwadaphnin Induces IFN-γ via PKD1/NF-κB/STAT1 Dependent Pathway in NK-92 Cells
Kang, H.-B., Ahn, K., Oh, S., & Kim, J. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115146 · Cited by 18
A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12
Klinke, D. J. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-242 · Cited by 18
MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions
Campbell, A. R., Duggan, M. C., Suarez‐Kelly, L. P., Bhave, N. S., Opheim, K. S., McMichael, E. L., Trikha, P., Parihar, R., Luedke, E. A., Lewis, A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0005 · Cited by 18
Self-citationCapuano, C., Pighi, C., Maggio, R., Battella, S., Morrone, S., Palmieri, G., Santoni, A., Klein, C., & Galandrini, R. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02482-2 · Cited by 15
Monocyte/Macrophage: NK Cell Cooperation—Old Tools for New Functions
Wałajtys-Rode, E., & Dzik, J. M. (2017) · Results and problems in cell differentiation · doi:10.1007/978-3-319-54090-0_5 · Cited by 15
Duggan, M. C., Campbell, A. R., McMichael, E. L., Opheim, K. S., Levine, K. M., Bhave, N. S., Culbertson, M. C., Noel, T. C., Yu, L., & Carson, W. E. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1381813 · Cited by 15
Self-citationImmune Modulation with Interleukin‐21
Bhave, N. S., & Carson, W. E. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05071.x · Cited by 15
Self-citationPatient’s Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers
Messaoudene, M., Frazao, A., Gavlovsky, P.-J., Toubert, A., Dulphy, N., & Caignard, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00683 · Cited by 15
Wang, J., Liu, T., & Chen, J. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2019.3084 · Cited by 14
Aram, J., Frakich, N., Morandi, E., Alrouji, M., Samaraweera, A. P. R., Onion, D., Spendlove, I., Colombo, S. L., Tănăsescu, R., Gran, B., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8070226 · Cited by 14
Kao, C., Mills, J. A., Burke, C. J., Morse, B. A., & Marques, B. F. (2023) · Biology · doi:10.3390/biology12050677 · Cited by 13
Tsuji, R. F., Ikado, K., & Fujiwara, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010064 · Cited by 13
Ansell, S. M. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000083325 · Cited by 13
Shin, B., Ge, S., Mirocha, J., Jordan, S. C., & Toyoda, M. (2017) · Transplantation Direct · doi:10.1097/txd.0000000000000653 · Cited by 12
Alakhras, N. S., Qiu, J., Rocha, G. V., Witcher, D. R., Köester, A., You, J., Schaer, D., Holmgaard, R., Driscoll, K. E., Willy, J. A., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1474996 · Cited by 11
Flip‐flops of natural killer cells in autoimmune diseases versus cancers: Immunologic axis
Shahrabi, S., Zayeri, Z. D., Ansari, N., Hadad, E. H., & Rajaei, E. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28421 · Cited by 11
The role of cytokine in regulation of the natural killer cell activity
Jurišić, V., Stojacic-Djenic, S., Čolović, N., & Konjević, G. M. (2008) · Srpski arhiv za celokupno lekarstvo · doi:10.2298/sarh0808423j · Cited by 11
Schneeberger, S., Kim, S. J., Eede, P., Boltengagen, A., Braeuning, C., Andreadou, M., Becher, B., Karaiskos, N., Kocks, C., Rajewsky, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.25.441313 · Cited by 11
Ogiji, E. D., Aboheimed, N., Ross, K., Voller, C., Siner, R., Jensen, R. L., Jolly, C., & Carr, D. F. (2024) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000993 · Cited by 10
Li, A., Cai, X., Li, D., Yu, Y., Liu, C., Shen, J., You, J., Qiao, J., & Wang, F. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s479741 · Cited by 10
Bejjani, A. T., Saab, S. A., Muhieddine, D. H., Habeichi, N. J., Booz, G. W., & Zouein, F. A. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000777 · Cited by 10
NK Cell–Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines
Jaime‐Ramirez, A. C., McMichael, E. L., Kondadasula, S., Skinner, C. C., Mundy-Bosse, B. L., Luedke, E. A., Jones, N., Mani, A., Roda, J. M., Karpa, V. I., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0168 · Cited by 10
Self-citationCurrent Immunotherapeutic Strategies in Breast Cancer
Carson, W. E., & Liang, M. I. (2007) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2007.07.008 · Cited by 10
Self-citationBiegert, G. W. G., Shaw, A. R., Morita, D., Porter, C., Matsumoto, R., Jatta, L., Crooks, N., Woods, M. L., Yao, Q. C., Parihar, R., et al. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.201006 · Cited by 9
Self-citationLee, N. Y., Hum, M., Tan, G. P., Seah, A. C., Ong, P.-Y., Kin, P. T., Lim, C. W., Samol, J., Tan, N. C., Law, H., et al. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01674-2 · Cited by 9
Benish, M., Melamed, R., Rosenne, E., Neeman, E., Sorski, L., Levi, B. Z., Shaashua, L., Matzner, P., & Ben‐Eliyahu, S. (2013) · Immunologic Research · doi:10.1007/s12026-013-8435-6 · Cited by 9
Intratumoral delivery of 4-1BBL boosts IL-12-triggered anti-glioma immunity
Lunavat, T. R., Nieland, L., van de Looij, S. M., de Reus, A. J. E. M., Couturier, C., Farran, C. A. E., Miller, T. E., Lill, J. K., Schübel, M., Xiao, T., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.028 · Cited by 9
Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy
Xue, F., Ren, X., Kong, C., Wang, J., Liu, L., Hu, J., Shen, N., & Tang, Z. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101239 · Cited by 8
Kobayashi, E., Motoi, S., Sugiura, M., Kajikawa, M., Kojima, S., Kohroki, J., & Masuho, Y. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.05.004 · Cited by 8
Luría-Pérez, R., Candelaria, P. V., Daniels‐Wells, T. R., Rodríguez, J. A., Helguera, G. F., & Penichet, M. L. (2019) · Cytokine · doi:10.1016/j.cyto.2019.04.004 · Cited by 8
Quiroga, D. M., Wesolowski, R., Zelinskas, S., Pinette, A., Benner, B. N., Schwarz, E. J., Savardekar, H., Johnson, C. W., Stiff, A. R., Yu, L., et al. (2024) · Cancer Control · doi:10.1177/10732748241250189 · Cited by 7
Self-citationWeiss, L., Schluck, M., Classens, R., de Jonge, P. K. J. D., van der Waart, A. B., Nguyen, K. G., Nguyen, T. T., Zaharoff, D. A., Malmberg, K., Dolstra, H., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.11.012 · Cited by 7
Hinterberger, M., Endt, K., Bathke, B., Habjan, M., Heiseke, A., Schweneker, M., Rohrscheidt, J. V., Atay, Ç., Chaplin, P. J., Kalla, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-32060-2 · Cited by 7
Evaluating Ovarian Cancer Chemotherapy Response Using Gene Expression Data and Machine Learning
Amniouel, S., Yalamanchili, K., Sankararaman, S., & Jafri, M. S. (2024) · BioMedInformatics · doi:10.3390/biomedinformatics4020077 · Cited by 7
McMichael, E. L., Courtney, N. B., Duggan, M. C., Wesolowski, R., Quiroga, D. M., Kondadasula, S. V., Atwal, L. S., Bhave, N. S., Luedke, E. A., Jaime‐Ramirez, A. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1312045 · Cited by 7
Self-citationCellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders
Hue, S. S., Ng, S., Wang, S., & Tan, S. (2022) · Cancers · doi:10.3390/cancers14102483 · Cited by 6
Luo, Y., Liu, J., Feng, W., Lin, D., Chen, M., & Zheng, H. (2024) · Evolutionary Bioinformatics · doi:10.1177/11769343241272413 · Cited by 5
List of some selected ptridophytes from Maidan valley of dir lower khyber Pakhtunkhwa Pakistan
Ullah, S., Sohil, M., Khattak, M., Ihsan, M., & Begum, L. (2019) · International Journal of Horticulture and Food Science · doi:10.33545/26631067.2019.v1.i2a.24 · Cited by 5
Kim, J. S., Kim, M. W., Jeong, H. Y., Kang, S. J., Park, S. I., Lee, Y. K., Kim, H. S., Kim, K. S., & Park, Y. S. (2016) · The Journal of Gene Medicine · doi:10.1002/jgm.2884 · Cited by 5
Bordignon, M. B., Viglietti, A. I. P., Juliá, E. P., Sánchez, M. B., Rölle, A., Mandó, P., Sabatini, L., Ostinelli, A., Rizzo, M., Barrio, M. M., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03448-w · Cited by 4
Moran, J., Mylod, E., Kane, L. E., Marion, C., Keenan, E., Mekhaeil, M., Lysaght, J., Dev, K. K., O'Sullivan, J. N., & Conroy, M. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020360 · Cited by 4
Ongaro, T., Guarino, S. R., Scietti, L., Palamini, M., Wulhfard, S., Neri, D., Villa, A., & Forneris, F. (2021) · Journal of Structural Biology · doi:10.1016/j.jsb.2021.107696 · Cited by 4
Interleukin-12 Implication in Tumor Initiating Capacity of Colorectal Cancer Stem Cells
Xiang, L., & Liang, H. (2016) · Chemotherapy Open access · doi:10.4172/2167-7700.1000209 · Cited by 3
CLCF1 promotes IL12Rβ2 proteolysis and limits Th1 differentiation
Laplante, V., Rousseau, M., Pasquin, S., Bourel, C., Uriarte, M., Affar, E. B., Najmanovich, R., Lesage, S., & Gauchat, J. (2025) · Cytokine · doi:10.1016/j.cyto.2025.156989 · Cited by 2
Liu, Z., Li, H., Gao, Z., Cheng, R., Lu, J., Che, X., Dong, J., Wang, Z., Cui, Z., Gu, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1684842 · Cited by 2
Cohen, E. N., Gao, H., Tin, S., Wu, Q., Ivan, C., Ueno, N. T., Woodward, W. A., Reuben, J. M., & Anfossi, S. (2026) · Breast Cancer Research · doi:10.1186/s13058-025-02174-8 · Cited by 2
Zagożdżon, R., & Lasek, W. (2016) · SpringerBriefs in immunology · doi:10.1007/978-3-319-46906-5_1 · Cited by 2
Stiene, D. S., Osterburg, A. R., Corsarie, L. B., Balzarini, N. R., Medvedovic, M., & Borchers, M. T. (2025) · Journal of Cellular Immunology · doi:10.33696/immunology.7.227 · Cited by 2
Thomassen, M., Tan, Q., Burton, M., & Kruse, T. A. (2013) · Cancer Informatics · doi:10.4137/cin.s12840 · Cited by 2
The Functionality of Kurozu and Kurozumoromimatsu
Tomoko, U. E. N. O. (2011) · JOURNAL OF THE BREWING SOCIETY OF JAPAN · doi:10.6013/jbrewsocjapan.106.183 · Cited by 2
Khan, S. (2018) · uO Research (University of Ottawa) · doi:10.20381/ruor-22198 · Cited by 2
Role of the Immune System in Cancer Development and Therapeutic Implications
Multhoff, G., & Astner, S. T. (2009) · Medical radiology · doi:10.1007/978-3-540-74386-6_7 · Cited by 1
Antitumor and Immunostimulation Effects of Kurozu in Tumor-bearing Mice
Ueno, T., Fujii, A., Nagano, M., Hou, D., & Fujii, M. (2010) · NIPPON SHOKUHIN KOGYO GAKKAISHI · doi:10.3136/nskkk.57.408 · Cited by 1
Antibody and Other Immune-Based Therapies for Myeloma
Munshi, N. C., & Tai, Y. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-564-0_12 · Cited by 1
Enhancing Immunotherapy for Cancer by Targeting Suppressive Myeloid cells
Benner, B. N. (2020) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Characterisation of CD8neg and CD8+ human natural killer cell subsets
Abdalla, I. I. I. (2012) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York) · Cited by 1
Regulation of T Cell-Dependent Humoral Immunity Through CD137 (4-1BB) Mediated Signals
Mittler, R. S., Niu, L., Hewes, B., & Foell, J. L. (2007) · Springer eBooks · doi:10.1007/0-387-32829-7_5 · Cited by 1
Regulation of FasL expression, and delineation of differentiation states of cytotoxic lymphocytes
Juang, S. W. W. (2015) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3qb9vd6v · Cited by 1
Wesa, A. K., & Mailliard, R. B. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-370454-2.00018-1 · Cited by 1
Anti-tumor and pro-tumor interactions of human NK cells in cancer
Wong, J. L. (2013) · D-Scholarship@Pitt (University of Pittsburgh)
Rafting with the IL-12 receptor
McVicar, D. W. (2008) · Blood · doi:10.1182/blood-2008-01-134627
Characterization of the natural killer cell cytokine response to antibody-coated tumor cells.
Parihar, R. (2004) · OhioLink ETD Center (Ohio Library and Information Network)
Self-citationRole of Interleukin-21 and the Interleukin-21 Receptor in Natural Killer Cell Activation
McMichael, E. L. (2016) · OhioLink ETD Center (Ohio Library and Information Network)
Antitumor Effects of IL-12 in Preclinical Studies
Lasek, W., & Jakóbisiak, M. (2016) · SpringerBriefs in immunology · doi:10.1007/978-3-319-46906-5_2
Natural Killer Cells in the Near Future of Immuno-Oncological Therapeutic Approaches
Tayebi, H. M. E. (2017) · InTech eBooks · doi:10.5772/intechopen.70567
Enhancing Immune Therapy for Cancer by Targeting Myeloid Derived Suppressor Cells
Stiff, A. R. (2017) · OhioLink ETD Center (Ohio Library and Information Network)
Aram, J. (2018) · Nottingham ePrints (University of Nottingham)
Natural Killer Cells and Alzheimer’s Disease
Page, A. Y. L., Dupuis, G., & Fülöp, T. (2018) · Springer eBooks · doi:10.1007/978-3-319-64597-1_146-1
Potentiating Cancer Immunotherapy with Antigen-Agnostic Therapies
van Vloten, J. P. (2020) · The Atrium (University of Guelph)
Identification of Signaling Pathways Involved in Ebola Virus Entry Into Host Cells
Stewart, C. M. (2021) · uO Research (University of Ottawa) · doi:10.20381/ruor-26534
Enhancing Anti-Cancer Properties of Human Natural Killer Cells
Fitzgerald, A. A. (2021) · DigitalGeorgetown (Georgetown University Library)
Pinho, M. J. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/b35a-e035
Zhang, S., Huntington, K. E., Zhou, L., Seyhan, A. A., Kun, B., Carneiro, B. A., Kreiling, J. A., Sedivy, J. M., & El‐Deiry, W. S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.30.569479
Metadata
- Authors
- Parihar, R., Dierksheide, J., Hu, Y., & Carson, W. E.
- Affiliations
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The Ohio State University (US)
- Corresponding author
- Carson, William E.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-10-01
- Volume
- 110
- Issue
- 7
- Pages
- 983-992
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4237052860
- Cited by
- 23
- References
- 40
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 1 · 2020: 2 · 2019: 2 · 2018: 2 · 2015: 2 · 2014: 1 · 2013: 1
- FWCI
- 0.11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Funders
- Ohio State University
- National Institutes of Health
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- IL-12, natural killer cells, monoclonal antibodies, antitumor immunity, FcγRIII, IL-12 receptor, monocytes, antibody-dependent cellular cytotoxicity, anti-idiotypic antibodies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.